Inactive Instrument

OKYO Pharma Limited London S.E.

OKYO

GG00BMFG5F62

Andrew Gutmann Ceases as Director of West African Minerals Corporation

January 10, 2018 at 11:15 am

The Board of West African Minerals Corporation announced that at the General Meeting held on 10 January 2018, Andrew Gutmann has ceased to be a Director with effect from the conclusion of the General Meeting on the basis that the company is now embarking on a new direction.

Latest news about OKYO Pharma Limited

OKYO Pharma Limited Announces Promising Categorical Data from OK-101 Phase 2 Trial in Dry Eye Disease	07-10	CI
H.C. Wainwright Adjusts Price Target on OKYO Pharma to $7 From $6, Maintains Buy Rating	03-22	MT
OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101	03-22	CI
OKYO Pharma Limited to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial	03-20	CI
Sector Update: Health Care Stocks Mixed in Afternoon Trading	02-09	MT
Sector Update: Health Care	02-09	MT
OKYO Pharma Rising After FDA Approves Phase 2 Trial of Prospective Treatment for Cornea Eye Pain	02-09	MT
Okyo Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain	02-09	CI
OKYO Pharma Limited Announces Appointment of Scientific Advisory Board	01-31	CI
OKYO Pharma Limited Reports Positive Safety and Efficacy Results in Its Phase 2, Randomized, Double-Masted, Placebo-Controlled Trial Evaluating the Safety and Efficacy of OK-101 Ophthalmic Solution in Patients with Dry Eye Disease	01-08	CI
Okyo Pharma Limited Announces Last Patient Enrolled in OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease Has Completed Final Protocol Visit	12-04	CI
HC Wainwright Initiates Coverage on OKYO Pharma with Buy Rating, $4 Price Target	11-02	MT
Sector Update: Health Care Stocks Lean Lower Premarket Monday	09/10/23	MT
OKYO Pharma Submits Investigational New Drug Application for OK-101 in Neuropathic Corneal Pain	09/10/23	MT
Okyo Pharma Limited Announces Filing of an Investigational New Drug Application for Ok-101 to Treat Neuropathic Corneal Pain	09/10/23	CI
OKYO Pharma Limited Announces Positive Safety Data Profile for the ongoing OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease	05/10/23	CI
Traders Digest Fresh Batch of Data, Stifling US Equity Futures Pre-Bell	15/09/23	MT
Top Premarket Decliners	15/09/23	MT
Sector Update: Health Care Stocks Rising Late Afternoon	14/09/23	MT
Sector Update: Health Care Stocks Rising in Afternoon Trading	14/09/23	MT
OKYO Pharma Prices $4 Million Share Offering	14/09/23	MT
Top Premarket Decliners	14/09/23	MT
OKYO Pharma Plans Share Offering; Stock Down After-Hours	13/09/23	MT
Top Premarket Decliners	13/09/23	MT
Okyo Pharma Limited Completes Enrollment in Phase 2 Clinical Trial of Ok-101 to Treat Dry Eye Disease	08/09/23	CI

Chart OKYO Pharma Limited

Duration

Period

More charts

Company Profile

OKYO Pharma Limited is a United Kingdom-based clinical stage biopharmaceutical company developing therapies for the treatment of dry eye disease (DED) and neuropathic corneal pain (NCP). The Company is focused on the discovery and development of novel molecules to treat inflammatory DED and ocular pain. Its research program is focused on a novel G Protein-Coupled Receptor (GPCR). The Company is developing OK-101, its lead preclinical product candidate, for the treatment of DED. OK-101 is focused on keratoconjunctivitis sicca, commonly referred to as DED, which is a multifactorial disease caused by an underlying inflammation resulting in the lack of lubrication and moisture in the surface of the eye. The Company also plans to evaluate its potential in benefiting patients with ocular neuropathic pain, uveitis and allergic conjunctivitis. It is also evaluating OK-201, a bovine adrenal medulla (BAM), lipidated-peptide preclinical analogue candidate that is in the developmental stage.

Sector

Pharmaceuticals

Calendar

29/07/2024 - Q4 2024 Earnings Release (Projected)

More about the company

Sector Biopharmaceuticals

	1st Jan change	Capi.
CSL LIMITED	+7.46%	100B
SAMSUNG BIOLOGICS CO.,LTD.	+8.42%	42.34B
BIOGEN INC.	-13.04%	32.76B
UCB	+79.97%	29.46B
BIOMARIN PHARMACEUTICAL INC.	-10.92%	16.31B
INCYTE CORPORATION	+1.93%	14.39B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-6.77%	12.23B
ALTEOGEN INC.	+177.16%	10.47B
SWEDISH ORPHAN BIOVITRUM AB	+1.50%	8.97B

Biopharmaceuticals